In this project UNSPF collected and analyzed data on state-of-the-art and use of AI in personalized nanomedicine, EVO-NANO platform performance requirements, regulatory requirements and potential customers and partners. At the same time MADISI collected and analyzed data related to commercialization, commercial due diligence, valuation and market strategy.
These two partners analyzed preliminary positioning and jointly formulated range of marketable applications, IP strategy and market strategy. Based on that analysis UNSPF defined which updates and modifications should be performed on EVO-NANO platform so it can be better tailored towards market application.
The work was carried in several phases.
In the first phase we performed Initial IP Position and Strength analysis and reported results in D1.1. In short we analyzed IP strengths and risks of the EVO-NANO platform and performed IP review through analysis of publications and patent trends for various metrices. Finally we defined IP as “A computational program that predicts how nano-therapies will interact with cancerous tumors”, while the market for this platform will fall within AI (Artificial Intelligence) and cancer treatment prognosis.
In the second phase we performed Macro Market analysis (reported in D1.2). There we analyzed how the EVO-NANO platform can be positioned on market and what methodology should be used. After that, we gave an overview of Regulatory procedures, in both the USA and EU and analyzed Nano-medicine market (both in total and for cancer treatment), its ongoing trends, most prominent companies and FDA-approved nano-drugs. We also analyzed AI medicine marked where we present the overall trend, market segmentation and cmpanies involved in AI therapies. We concluded that there is a growing niche for the innovation contained in this project.
Third phase focused on Application Analysis (reported in D1.3). There we analyzed specific application performance requirements and regulations, specific costs and price points, and know potential customers/partners. We performed interviews with representatives of related companies and the main conclusion is that this is a niche & early stage market segment with very long development time and associated high investment cost.
Finally, we outlined a market strategy (reported in D1.4). Main points are:
• Because private investors have been found to be reluctant, it can therefore be determined that the best method forward will be further grants;
• The need for this technology has been reaffirmed;
• At this moment, the EVO-NANO technology lacks the necessary functionality and tangibility to be patent protected;
• Therefore, in the future, planning should include the product as a service unless the technology has been absorbed into upstream activities, including a fully developed AI platform that has shown proven efficacy in predicting outcomes in drug development.
